Compare ASE Technology Holding Co Ltd (ASX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? ASE Technology Holding Co Ltd trades at $41.77 (market cap $87.94B), while Vertex Pharmaceuticals Incorporated trades at $475.52 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and ASE Technology Holding Co Ltd pays a 1.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ASX | VRTX | |
|---|---|---|
Market Cap | $87.94B | $120.89B |
Sector | Technology | Health |
52-Week High | $45.12 | $529.59 |
52-Week Low | $9.50 | $366.54 |
Enterprise Value | $92.38B | $115.63B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $40.56, down 4.92% over 24 hours, with a neutral technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust cash flow growth. Revenue reached $645.39B in 2025 with net income of $40.02B, while analyst sentiment remains positive with 80% buy ratings. Recent news highlights AI-driven packaging demand and LEAP business growth exceeding $3.5B in 2026 revenue outlook.
The stock presents growth potential from AI infrastructure demand and margin expansion, though elevated P/E ratio of 63.65 suggests premium valuation. Key risks include semiconductor cycle volatility and execution challenges in scaling advanced packaging capacity. Institutional ownership trends and positive earnings revisions support the bullish case, but investors should monitor competitive pressures in the semiconductor packaging sector.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
